Subject Award · Social Sciences · 2026
The ten finalist universities are the ten highest-ranked on the Decision Sciences collaboration index, listed here alphabetically until the full index publishes on 15 September. Each finalist is represented by an academic whose recent work exemplifies why: a real project, drawn from the open scholarly record, cited so you can check it.
The finalists
Science is stronger when anyone can retrace every step behind a result. The team created the first executable paper in heliophysics, an interactive document that places the publication's text alongside its code, data and dependencies in a containerised environment, and presents an adaptable workflow for comparing magnetosphere models with spacecraft observations.
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Systematic reviews underpin evidence-based decisions across science and medicine, and readers need to see clearly why a review was done, what its authors did, and what they found. The project presents the PRISMA 2020 statement, a 27-item checklist with expanded guidance and revised flow diagrams that updates the 2009 standard to reflect a decade of advances in identifying, selecting, appraising and synthesising studies.
New generation antidepressants for depression in children and adolescents: a network meta-analysis
Major depressive disorder affects children's education, relationships and wellbeing, and clinicians face a growing range of newer antidepressant medications. Using network meta-analysis, the study compared the effectiveness and safety of newer generation antidepressants for young people with diagnosed depression, examining depression outcomes, functioning and suicide-related outcomes alongside the influence of age, treatment duration, severity and industry funding.
A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas
Guidance is most powerful when it travels across languages. Presented here in Portuguese translation, the PRISMA 2020 statement updates the 2009 reporting guideline for systematic reviews, offering a 27-item checklist, an abstract checklist and revised flow diagrams that reflect a decade of advances in how studies are identified, selected, appraised and synthesised.
COSMIN guideline for systematic reviews of patient-reported outcome measures version 2.0
Choosing the right questionnaire to capture patients' own experience of their health is harder than it sounds. The work updates the COSMIN guideline for systematic reviews of patient-reported outcome measures, including its risk-of-bias checklist and criteria for good measurement properties, placing fresh emphasis on well-defined research questions, comprehensive search strategies and rigorous assessment.
BindingDB in 2024: a FAIR knowledgebase of protein-small molecule binding data
Behind many advances in medicinal chemistry sits carefully curated data. The work reports the 2024 update of BindingDB, a public database of experimentally measured binding affinities that now holds 2.9 million measurements spanning 1.3 million compounds and thousands of protein targets, supporting applications from biochemical pathway annotation to the training of artificial intelligence models.
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Transparent reporting is what lets readers judge a systematic review on its merits. Replacing the original 2009 guideline, the PRISMA 2020 statement offers an updated 27-item checklist with detailed reporting recommendations, an abstract checklist and revised flow diagrams, restructured so that a decade of advances in review methodology can be put into practice more easily.
Why do vivid, surprising or prominent things sway our choices more than they should? Reviewing fast-growing research on salience, the work shows how bottom-up attention can distort economic decisions, unifying probability weighting, menu effects, reference points and framing within one approach, and pointing to potential applications in finance, industrial organisation, advertising and politics.
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Systematic reviews underpin decisions in healthcare and beyond, but they are only as useful as their reporting is transparent. This work presents PRISMA 2020, an updated 27-item checklist with detailed recommendations and revised flow diagrams, helping reviewers explain clearly why a review was done, what the authors did, and what they found.
Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane
Judging whether the results of randomised controlled trials can be trusted is central to any systematic review. Drawing on Cochrane's phased introduction of the Risk of Bias 2 tool, launched in 2019 to improve usability and reflect current understanding of how the causes of bias influence study results, the work distils practical guidance and learning for systematic reviewers.
Exclusive to partners
Partners verify their data, feature their academics, and are eligible for the Subject Awards. Finalists are identified from open data; winners are decided by our editorial team and announced on 15 September 2026.
Explore partnership →The wider slate
CONSORT 2025 statement: updated guideline for reporting randomised trials
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Rapid reviews: the pros and cons of an accelerated review process
CONSORT 2025 statement: updated guideline for reporting randomised trials
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
CONSORT 2025 statement: updated guideline for reporting randomised trials
The Galaxy platform for accessible, reproducible, and collaborative data analyses: 2024 update